Medial EarlySign closed a $30 million series B financing round, bringing its funding total to $50 million.
Medial Early Sign uses an artificial intelligence-based algorithm platform to help healthcare organizations optimize care and prevent or delay serious complications. The company is in the midst of developing a series of stratification products that it believes will detect various cancers, diabetes and other life-threatening conditions.
Here's what you should know:
1. AMoon Fund was the lead investor, followed by Horizons Ventures and Nir Kalkstein, a co-founder of Medial EarlySign.
2. Company CEO Ori Geva said, "This funding will allow us to further broaden our suite of solutions, and expand clinical research and global implementations of our clinically-supported technology. The insights we enable could bring added value to almost every interaction with the patient, with the potential to positively impact millions of lives."
3. The company's products are being evaluated in ongoing clinical data studies taking place at more than 14 institutions around the world.